VeriSilicon’s Scalable High-Performance GPGPU-AI Computing IPs Empower Automotive and Edge Server AI Solutions
Provide AI acceleration with high computing density, multi-chip scaling, and 3D-stacked memory integration
VeriSilicon (688521.SH) today announced the latest advancements in its high-performance and scalable GPGPU-AI computing IPs, which are now empowering next-generation automotive electronics and edge server applications. Combining programmable parallel computing with a dedicated Artificial Intelligence (AI) accelerator, these IPs offer exceptional computing density for demanding AI workloads such as Large Language Model (LLM) inference, multimodal perception, and real-time decision-making in thermally and power-constrained environments.
VeriSilicon’s GPGPU-AI computing IPs are based on a high-performance General Purpose Graphics Processing Unit (GPGPU) architecture with an integrated dedicated AI accelerator, delivering outstanding computing capabilities to AI applications. The programmable AI accelerator and sparsity-aware computing engine accelerate transformer-based and matrix-intensive models through advanced scheduling techniques. These IPs also support a broad range of data formats for mixed-precision computing, including INT4/8, FP4/8, BF16, FP16/32/64, and TF32, and are designed with high-bandwidth interfaces of 3D-stacked memory, LPDDR5X, HBM, as well as PCIe Gen5/Gen6 and CXL. They are also capable of multi-chip and multi-card scale-out expansion, offering system-level scalability for large-scale AI application deployments.
VeriSilicon’s GPGPU-AI computing IPs provide native support for popular AI frameworks for both training and inference, such as PyTorch, TensorFlow, ONNX, and TVM. These IPs also support General Purpose Computing Language (GPCL) which is compatible with mainstream GPGPU programming languages, and widely used compilers. These capabilities are well aligned with the computing and scalability requirements of today’s leading LLMs, including models such as DeepSeek.
“The demand for AI computing on edge servers, both for inference and incremental training, is growing exponentially. This surge requires not only high efficiency but also strong programmability. VeriSilicon’s GPGPU-AI computing processors are architected to tightly integrate GPGPU computing with AI accelerator at fine-grained levels. The advantages of this architecture have already been validated in multiple high-performance AI computing systems,” said Weijin Dai, Chief Strategy Officer, Executive Vice President, and General Manager of the IP Division at VeriSilicon. “The recent breakthroughs from DeepSeek further amplify the need for maximized AI computing efficiency to address increasingly demanding workloads. Our latest GPGPU-AI computing IPs have been enhanced to efficiently support Mixture-of-Experts (MoE) models and optimize inter-core communication. Through close collaboration with multiple leading AI computing customers, we have extended our architecture to fully leverage the abundant bandwidth offered by 3D-stacked memory technologies. VeriSilicon continues to work hand-in-hand with ecosystem partners to drive real-world mass adoption of these advanced capabilities.”
About VeriSilicon
VeriSilicon is committed to providing customers with platform-based, all-around, one-stop custom silicon services and semiconductor IP licensing services leveraging its in-house semiconductor IP. For more information, please visit: www.verisilicon.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20250608814759/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Uniphore Launches Business AI Cloud: A Sovereign, Composable & Secure AI Platform to Power the Agentic Enterprise9.6.2025 15:04:00 CEST | Press release
New platform unifies agents, models, knowledge, and data to finally deliver on the promise of AI as a transformative force for business Uniphore, the Business AI company, today launched the Uniphore Business AI Cloud: a sovereign, composable, and secure platform that bridges the “AI divide” between IT and business users by combining the simplicity of consumer AI with enterprise-grade security and scalability. While AI technologies rapidly reshape the enterprise, there has been little focus on deploying AI in a way that empowers CIOs to scale it securely across the organization while enabling business users to intuitively access AI with the full power of enterprise data, integrations, and context. IT and business must be united through a single AI platform to fulfill AI’s promise as a transformative force for business. Introducing the Business AI Cloud Uniphore’s Business AI Cloud powers the agentic enterprise with a full-stack AI platform spanning data, knowledge, models, and agents. I
Capcom’s Resident Evil Requiem, the Latest Title in the Series, Set to Release on February 27, 2026!9.6.2025 15:00:00 CEST | Press release
– The highly anticipated new installment to launch during the series’ 30th anniversary – Capcom Co., Ltd. (TOKYO:9697) today announced that Resident Evil Requiem, the latest title in the Resident Evil series, is scheduled for release on February 27, 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250609946595/en/ Resident Evil Requiem Logo Resident Evil Requiem is a survival horror game that serves as the ninth main installment in the series. The title is being developed using RE ENGINE, Capcom’s proprietary game engine, and leverages Capcom’s extensive development expertise cultivated through numerous hit titles. The graphical fidelity has undergone a significant evolution in particular, delivering visuals with cinematic realism that vividly convey characters’ emotions and offer an unprecedented level of immersion. The company is developing the title steadily to meet the high expectations of both long-time series’ fans
Avanzanite Announces Pan-European Partnership with Agios to Launch PYRUKYND® in Rare Blood Disorders9.6.2025 14:40:00 CEST | Press release
PYRUKYND® (mitapivat) is a first-in-class pyruvate kinase (PK) activator, approved by the European Commission for adults with PK deficiency The agreement includes commercialization and distribution rights for potential future indications Furthered by this partnership with Agios, Avanzanite is setting a new paradigm in biotech commercial and distribution partnerships, and in how orphan medicines reach patients across Europe Avanzanite Bioscience B.V. (“Avanzanite”), a fast-growing commercial-stage specialty pharmaceutical company dedicated to bringing rare disease medicines to patients across Europe, announced today an exclusive agreement with Agios Pharmaceuticals Inc. (Nasdaq: AGIO), a Boston-based biotech company focused on the development and commercialization of rare disease medicines. Under the agreement, Avanzanite will commercialize and distribute PYRUKYND® (mitapivat) across the European Economic Area, the UK and Switzerland. This press release features multimedia. View the ful
Tier-1 MVNO Selects Tecnotree’s AI-Native BSS for Multi-Country Transformation Across UK & Europe9.6.2025 14:36:00 CEST | Press release
Tecnotree, the global pioneer in AI-native Digital BSS and fintech platforms, has announced a major multi-year, multi-country agreement with a Tier-1 Mobile Virtual Network Operator (MVNO) to transform its operations across the United Kingdom and Europe. The deal, valued at USD 19.58 million over five years, positions Tecnotree at the forefront of next-generation MVNO enablement in mature, highly competitive telecom markets. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250609328949/en/ This engagement will see the full-stack replacement of the MVNO’s legacy systems with Tecnotree’s composable, cloud-native BSS—an AI-first, TM Forum ODA-aligned platform engineered for speed, scale, and interoperability. Designed to unlock real-time personalization, agile service orchestration, and embedded financial ecosystems, this transformation lays the foundation for the MVNO to compete with intelligence and grow with intent. The deploy
Innospera Pharma Appoints Dr. Glenn Crater as Chief Medical Officer to Support Advancement of ING-006 Toward the Clinic9.6.2025 14:00:00 CEST | Press release
Innospera Pharma Inc. (“Innospera”), a private, near-clinical-stage biotechnology company advancing differentiated small molecule modulators of GPR84 and GPR40 to treat inflammatory and metabolic diseases, today announced the appointment of Dr. Glenn Crater, MD, FCCP as Chief Medical Officer (CMO). Glenn will start immediately as a fractional CMO, with the commitment to joining full time as the Company’s lead compound reaches the clinic. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250609975546/en/ Glenn Crater, MD, FCCP, appointed Chief Medical Officer of Innospera Pharma Dr. Crater brings to Innospera over 25 years of clinical, regulatory, and leadership experience in pulmonary medicine and drug development. A board-certified pulmonologist, Dr. Crater has played pivotal roles in advancing respiratory drug candidates, with particular expertise in Idiopathic Pulmonary Fibrosis (IPF) — the initial target indication for Inno
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom